PE20001543A1 - Derivados de piridopiranoacepinas, su preparacion y su aplicacion en terapeutica - Google Patents

Derivados de piridopiranoacepinas, su preparacion y su aplicacion en terapeutica

Info

Publication number
PE20001543A1
PE20001543A1 PE2000000187A PE0001872000A PE20001543A1 PE 20001543 A1 PE20001543 A1 PE 20001543A1 PE 2000000187 A PE2000000187 A PE 2000000187A PE 0001872000 A PE0001872000 A PE 0001872000A PE 20001543 A1 PE20001543 A1 PE 20001543A1
Authority
PE
Peru
Prior art keywords
alkyl
derivatives
preparation
pyridopyranoacepines
therapeutics
Prior art date
Application number
PE2000000187A
Other languages
English (en)
Inventor
Alistair Lochead
Frederic Galli
Samir Jegham
Axelle Samson
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of PE20001543A1 publication Critical patent/PE20001543A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A DERIVADOS DE PIRIDOPIRANOACEPINAS DE FORMULA I, DONDE R1 ES H, ALQUILO C1-C4, FENIL-ALQUILO C1-C4, FENILHIDROXI-ALQUILO C1-C4, FURANIL-ALQUILO C1-C4, FURANILHIDROXIALQUILO C1-C4; R2 ES H, HALOGENO, TRIFLUOROMETILO, CIANO, HIDROXI, NITRO, ACETILO, ALQUILO C1-C6, ALCOXI C1-C6, NR4R5; R4 ES H, ALQUILO C1-C4, ALCANOILO C1-C4; R5 ES H, ALQUILO C1-C4; O R4 Y R5 FORMAN CON N UN CICLO DE 4-7 MIEMBROS, FENILO O NAFTILO OPCIONALMENTE SUSTITUIDO CON HALOGENO, TRIFLUOROMETILO, TRIFLUOROMETOXI, ENTRE OTROS; R3 ES H, HALOGENOALQUILO C1-C4. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I TIENE AFINIDAD POR LOS RECEPTORES NICOTINICOS O4ß2 POR LO QUE PUEDE SER UTIL PARA EL TRATAMIENTO DE DESORDENES DEL SISTEMA NERVIOSO CENTRAL O DEL SISTEMA GASTROINTESTINAL, TRASTORNOS MOTORES, TRATAMIENTO DEL DOLOR
PE2000000187A 1999-03-05 2000-03-03 Derivados de piridopiranoacepinas, su preparacion y su aplicacion en terapeutica PE20001543A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9902784A FR2790474B1 (fr) 1999-03-05 1999-03-05 Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
PE20001543A1 true PE20001543A1 (es) 2001-03-18

Family

ID=9542888

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000187A PE20001543A1 (es) 1999-03-05 2000-03-03 Derivados de piridopiranoacepinas, su preparacion y su aplicacion en terapeutica

Country Status (37)

Country Link
US (2) US6538003B1 (es)
EP (1) EP1161434B1 (es)
JP (1) JP4806123B2 (es)
KR (2) KR100768355B1 (es)
CN (1) CN1137894C (es)
AR (1) AR022820A1 (es)
AT (1) ATE231869T1 (es)
AU (1) AU764625B2 (es)
BG (1) BG65211B1 (es)
BR (1) BR0008763A (es)
CA (1) CA2372063C (es)
CO (1) CO5160250A1 (es)
CZ (1) CZ302259B6 (es)
DE (1) DE60001307T2 (es)
DK (1) DK1161434T3 (es)
EE (1) EE04497B1 (es)
ES (1) ES2191611T3 (es)
FR (1) FR2790474B1 (es)
HK (1) HK1040398B (es)
HR (1) HRP20010655B1 (es)
HU (1) HU228671B1 (es)
ID (1) ID30116A (es)
IL (2) IL145150A0 (es)
MX (1) MXPA01008972A (es)
NO (1) NO327119B1 (es)
NZ (1) NZ513561A (es)
PE (1) PE20001543A1 (es)
PL (1) PL201683B1 (es)
RS (1) RS49997B (es)
RU (1) RU2238273C2 (es)
SK (1) SK284339B6 (es)
TR (1) TR200102403T2 (es)
TW (1) TWI222975B (es)
UA (1) UA61164C2 (es)
UY (1) UY26048A1 (es)
WO (1) WO2000053608A1 (es)
ZA (1) ZA200106811B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
BR0312297A (pt) 2002-07-18 2005-04-12 Cytos Biotechnology Ag Conjugados veìculos de hapteno e seu uso
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
CA2507502C (en) * 2002-12-06 2011-11-29 North Shore-Long Island Jewish Research Institute Inhibition of inflammation using alpha 7 receptor-binding cholinergic agonists
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US20080255203A1 (en) * 2007-04-12 2008-10-16 Abbott Laboratories Heterocyclic compounds and their methods of use
US20090076059A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched dianicline
WO2010009775A1 (de) 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
BRPI0820668A2 (pt) * 2007-12-07 2017-08-22 Abbott Gmbh & Co Kg Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina
US8703775B2 (en) * 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
CN102026995B (zh) * 2007-12-07 2014-10-29 Abbvie德国有限责任两合公司 5，6-二取代的羟吲哚衍生物和其用途
US8383657B2 (en) * 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
US20090221648A1 (en) * 2007-12-21 2009-09-03 Abbott Laboratories Compositions for treatment of cognitive disorders
JP2011516489A (ja) 2008-03-31 2011-05-26 ユニバーシティ・オブ・サウス・フロリダ 疾患誘発性運動失調症および非運動失調性平衡異常の治療法
ES2396300T3 (es) 2008-11-19 2013-02-20 Envivo Pharmaceuticals, Inc. Tratamiento de trastornos cognitivos con (R)-7-cloro-N-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
CN102802620A (zh) * 2009-05-11 2012-11-28 英维沃医药有限公司 使用某种α-7烟酸受体与乙酰胆碱酯酶抑制剂结合治疗认知障碍
US9040568B2 (en) * 2009-05-29 2015-05-26 Abbvie Inc. Pharmaceutical compositions for the treatment of pain
WO2011146511A1 (en) 2010-05-17 2011-11-24 Envivo Pharmaceuticals, Inc. A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301660D0 (en) * 1993-01-28 1993-03-17 Smithkline Beecham Plc Pharmaceuticals
JPH11512443A (ja) * 1995-09-22 1999-10-26 ノボ ノルディスク アクティーゼルスカブ 新規な置換アザ環式またはアザ二環式化合物
FR2761072B1 (fr) * 1997-03-20 1999-04-23 Synthelabo Derives de 2,3-dihydrofuro[3,2-b]pyridine, leur preparation et leur application en therapeutique
ATE254618T1 (de) * 1997-05-30 2003-12-15 Neurosearch As Spiro chinuclidin-derivate, ihre herstellung und verwendung
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds

Also Published As

Publication number Publication date
RU2238273C2 (ru) 2004-10-20
US20030187012A1 (en) 2003-10-02
HUP0201753A3 (en) 2004-12-28
HRP20010655A2 (en) 2002-08-31
CN1343208A (zh) 2002-04-03
HUP0201753A2 (en) 2002-09-28
EP1161434B1 (fr) 2003-01-29
IL145150A0 (en) 2002-06-30
FR2790474A1 (fr) 2000-09-08
DK1161434T3 (da) 2003-05-26
ZA200106811B (en) 2002-08-19
HK1040398B (zh) 2003-07-18
SK284339B6 (sk) 2005-02-04
JP4806123B2 (ja) 2011-11-02
US6538003B1 (en) 2003-03-25
RS49997B (sr) 2008-09-29
PL201683B1 (pl) 2009-04-30
CA2372063A1 (en) 2000-09-14
PL352330A1 (en) 2003-08-11
UY26048A1 (es) 2000-09-29
US6908927B2 (en) 2005-06-21
HU228671B1 (en) 2013-05-28
EE200100470A (et) 2002-12-16
UA61164C2 (uk) 2003-11-17
FR2790474B1 (fr) 2001-04-06
AR022820A1 (es) 2002-09-04
ES2191611T3 (es) 2003-09-16
EE04497B1 (et) 2005-06-15
AU764625B2 (en) 2003-08-28
IL145150A (en) 2007-06-03
JP2002539129A (ja) 2002-11-19
HK1040398A1 (en) 2002-06-07
TWI222975B (en) 2004-11-01
NZ513561A (en) 2003-06-30
MXPA01008972A (es) 2002-03-27
BG105828A (bg) 2002-03-29
BR0008763A (pt) 2002-01-02
WO2000053608A1 (fr) 2000-09-14
CO5160250A1 (es) 2002-05-30
CN1137894C (zh) 2004-02-11
CZ20013102A3 (cs) 2002-01-16
NO20014270L (no) 2001-11-05
HRP20010655B1 (en) 2003-06-30
AU2922600A (en) 2000-09-28
BG65211B1 (bg) 2007-07-31
EP1161434A1 (fr) 2001-12-12
KR100768355B1 (ko) 2007-10-17
YU59601A (sh) 2004-03-12
CA2372063C (en) 2011-01-11
TR200102403T2 (tr) 2001-12-21
ID30116A (id) 2001-11-08
ATE231869T1 (de) 2003-02-15
KR20070086359A (ko) 2007-08-27
NO327119B1 (no) 2009-04-27
NO20014270D0 (no) 2001-09-03
CZ302259B6 (cs) 2011-01-19
KR20010102492A (ko) 2001-11-15
DE60001307D1 (de) 2003-03-06
DE60001307T2 (de) 2003-12-11
SK12422001A3 (sk) 2002-04-04

Similar Documents

Publication Publication Date Title
PE20001543A1 (es) Derivados de piridopiranoacepinas, su preparacion y su aplicacion en terapeutica
PE20020228A1 (es) Compuestos organicos como inhibidores de 3',5' guanosin monofosfato ciclico fosfodiesterasa
UY28150A1 (es) Agentes terapeuticos
CO5680438A2 (es) Uso de derivados de ciclotiocarbamato en tratamiento de condiciones relacionadas con hormonas
PE20001600A1 (es) Derivados de 1,4-diazabiciclo (3.3.2) nonan-4-carboxilatos y carboxamidas, su preparacion y su aplicacion en terapeutica
AR245700A1 (es) Nuevos derivados de la 2-anilino-pirimidina como agentes antiparasitarios.
PE20050482A1 (es) Derivados de dihidrobenzofuranilo alcanamida
CR9459A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
ECSP034865A (es) Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas
PE20091066A1 (es) 5-[3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para su produccion y su uso como agentes antiinflamatorios
AR031597A1 (es) Compuestos piperidinos,un proceso para su preparacion, composiciones farmaceuticas,y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores ccr-3
PE20071251A1 (es) Derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
PE20050473A1 (es) Nuevos derivados de pirimidin-2-amina
PE20000055A1 (es) Compuestos de indol 2,3-sustituidos como agentes anti-inflamatorios y analgesicos
PE20060734A1 (es) Derivado de pirrol sustituido como antagonistas del receptor de androgenos
PE20050054A1 (es) Indoles 2,7-sustituidos
PE20040763A1 (es) Derivados de aminoalcoxiindoles como ligandos de los receptores 5-ht6
PE20021018A1 (es) DERIVADOS DE ß - CARBOLINA
PE20010956A1 (es) Derivados de isoquinolina y quinazolina con afinidad por los receptores de serotonina combinados 5-ht1a, 5-ht1b, 5-ht1d
PE20061092A1 (es) COMPUESTOS HETEROCICLICOS COMO AGONISTAS SELECTIVOS PARA EL RECEPTOR-ß DE ESTROGENO
PE20010995A1 (es) Dihidrobenzopiranos sustituidos y analogos de estos para el tratamiento de desordenes en los que interviene cox-2
PE47296A1 (es) Nuevo uso de derivado de indol
ES2058150T3 (es) Procedimiento para la obtencion de productos de reaccion del 2,2-bis(4-hidroxifenil)hexafluorpropano asi como estos nuevos derivados.
AR052258A1 (es) Derivados de fenilpiperazinas con una afinidad combinada para receptores de dopamina - d2 y sitios de reabsorcion de serotonina, composiciones farmaceuticas que los contienen y su empleo como medicamentos para el tratamiento de enfermedades del sistema nervioso central.
PE20050120A1 (es) Camptotecinas con un anillo de lactona modificada

Legal Events

Date Code Title Description
FA Abandonment or withdrawal